DCDouglas C. Cheung

Douglas C. Cheung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Douglas C. Cheung has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Girish S. Kulkarni

    Affiliations Divisions of Urology and Surgical Oncology, Department of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, ICES, Toronto, Ontario, Canada, Division of Urology, Sprott Department of Surgery, University Health Network, Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

    2 shared publications
  • Alejandro Berlin

    Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada

    1 shared publication
  • Alexandre Zlotta

    Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada

    1 shared publication
  • Amanda E. Hird

    Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada

    1 shared publication
  • Amanda Elizabeth Hird

    Division of Urology, University of Toronto, Toronto, ON, Canada

    1 shared publication
  • Andrew B. Mendlowitz

    Toronto Centre for Liver Disease, University Health Network , Toronto, Ontario M5G 2C4

    1 shared publication

Latest Publications

  • Open Access

    The impact of the early COVID-19 pandemic on healthcare system resource use and costs in two provinces in Canada: An interrupted time series analysis

    by Seraphine Zeitouny, Douglas C. Cheung, Karen E. Bremner, Reka E. Pataky, Priscila Pequeno, John Matelski, Stuart Peacock, M. Elisabeth Del Giudice, Lauren Lapointe-Shaw, George Tomlinson, et al.

    Introduction: The aim of our study was to assess the initial impact of COVID-19 on total publicly-funded direct healthcare costs and health services use in two Canadian provinces, Ontario and British Columbia (BC).Methods: This retrospective repeated cross-sectional study used population-based administrative datasets, linked within each province, from January 1, 2018 to December 27, 2020. Interrupted time series analysis was used to estimate changes in the level and trends of weekly resource use and costs, with March 16–22, 2020 as the first pandemic week. Also, in each week of 2020, we identified cases with their first positive SARS-CoV-2 test and estimated their healthcare costs until death or December 27, 2020.Results: The resources with the largest level declines (95% confidence interval) in use in the first pandemic week compared to the previous week were physician services [Ontario: -43% (-49%,-37%); BC: -24% (-30%,-19%) (both p<0.001)] and emergency department visits [Ontario: -41% (-47%,-35%); BC: -29% (-35%,-23%) (both p<0.001)]. Hospital admissions declined by 27% (-32%,-23%) in Ontario and 21% (-26%,-16%) in BC (both p<0.001). Resource use subsequently rose but did not return to pre-pandemic levels. Only home care and dialysis clinic visits did not significantly decrease compared to pre-pandemic. Costs for COVID-19 cases represented 1.3% and 0.7% of total direct healthcare costs in 2020 in Ontario and BC, respectively.Conclusions: Reduced utilization of healthcare services in the overall population outweighed utilization by COVID-19 patients in 2020. Meeting the needs of all patients across all services is essential to maintain resilient healthcare systems.


  • Cost of Bladder Cancer Care: A Single-center Comparison of Radical Cystectomy and Trimodal Therapy

    by Diana E. Magee, Douglas C. Cheung, Amanda E. Hird, Peter Chung, Padraig Warde, Charles Catton, Alejandro Berlin, Alexandre Zlotta, Neil E. Fleshner, Girish S. Kulkarni

    Radical cystectomy (RC) and trimodal therapy (TMT) are both accepted options in the management of muscle invasive bladder cancer (MIBC). As such, we sought to evaluate the micro-level costs associated with both modalities. All patients undergoing TMT or RC for primary treatment of urothelial MIBC at a single academic centre between 2008 and 2012 were included. Direct costs associated with each phase of a patient's clinical course were collected from the hospital's financial department and physician costs were calculated based on the provincial fee schedule. Costs of radiation treatments were derived from previously published literature. A total of 137 patients were included. The mean patient age was 69 (+/-12). Overall, 89 (65%) patients underwent RC and 48 (35%) were treated with TMT. The RC group had higher rates of cT3/T4 compared to those in the TMT group (51% vs 26%, P < .001). The median cost in the treatment phase for RC was $30,577 (IQR: $23,908-$38,837) versus $18,979 (IQR: $17,271-$23,519) for TMT (P < .001). There was no significant difference between treatment groups with respect to cost of diagnosis or work up. However, the cost of follow up care was numerically higher for patients undergoing TMT compared to RC ($3,096/year vs $1,974/year, P = .09). In appropriately selected patients with MIBC where TMT costs are not prohibitive and are lower than in RC. With increasing follow up time after primary treatment, the cost difference between modalities may be mitigated by the need for bladder surveillance and salvage therapy in the TMT cohort.


  • Opioid Use After Nephrectomy for Kidney Cancer in Ontario: A Population-Based Study

    by D.C. Cheung, L.J. Martin, N.K. Jivraj, H. Clarke, T. Gomes, D.N. Wijeysundera, C. Diong, M. Nayan, O. Saarela, S.M.H. Alibhai, et al.


  • Treatment on active surveillance of small renal masses: Progression vs. preference

    by Douglas Cheung, Jed Frankel, Pavinder Tut, Maria Komisarenko, Lisa Martin, Michael Jewett, Antonio Finelli

    Introduction: Active surveillance (AS) of small renal masses (SRM) is increasingly recognized as a safe option. A recent U.S. study found that half of patients receiving treatment on AS were for preference, but these findings may not be generalizable to other jurisdictions and healthcare models. We aimed to investigate AS failure rates and causes among a contemporary biopsy-evaluated cohort in Canada. Methods: A retrospective review was performed of SRM patients on AS undergoing treatment at our tertiary care center (1999–2018). All patients had undergone renal biopsy and been diagnosed with renal cell carcinoma (RCC). Demographic and clinical parameters surrounding the decision to treat were extracted from chart review. Indications for treatment were dichotomized into clinical (radiographical) progression or preference. Qualitative assessment of clinic notes confirmed treatment indication. Ethics approval was obtained. Results: A total of 38 SRM-RCC patients who underwent treatment on AS were identified, of which 29 had been on AS ≥1 year. Most (75.9%) were male, and the mean age beginning AS was 65.9±9.0 years. Most patients had clear-cell RCC with low-grade disease. Seventeen of 29 (58.6%) patients experienced clinical progression after 3.82 (2.57–7.16) years, whereas preference accounted for 12/29 (41.4%) after 2.22 (1.69–3.53) years (time-to-treatment p=0.032). The longest duration on AS was 14.2 years prior to clinical progression. No patients had metastatic progression before treatment. Conclusions: Two-fifths of patients received treatment for preference and at a much higher rate vs. clinical progression. These findings suggest a clinical gap where effective patient counselling, prior to and during AS, may improve adherence.


  • Neoadjuvant Versus Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Microsimulation Model

    by Amanda E. Hird, Diana E. Magee, Douglas C. Cheung, Beate Sander, Srikala Sridhar, Robert K. Nam, Girish S. Kulkarni


  • Assessing the Necessity of Routine Crossmatching for Blood Transfusion in Renal Transplantation

    by Douglas Cheung, Luke Reynolds, Melin Peng, Jason Lee, Robert Stewart, Kenneth Pace, R. John D’aRcy Honey, Michael Ordon

    Introduction: Routine crossmatch of packed red blood cells (pRBCs) is completed preoperatively at many centers despite conflicting evidence on the incidence of blood transfusions with renal transplantation. In the current economic climate, resource adjudication should be judicious and medically appropriate. The objective of this study was to determine the incidence, timing, and predictors of early postoperative pRBC transfusion in patients undergoing renal transplantation. Methods: A retrospective review of all patients undergoing renal transplantation at our institution from January 2013 to May 2016 was performed. Demographic, biochemical, and clinical parameters were recorded. The primary outcome was early postoperative transfusion, defined as an intraoperative transfusion or within 2 days of surgery. Multivariable logistic regression was performed to identify associations with early postoperative transfusion. Results: We identified 428 patients during the study period (average age 55 years, 60% male, 30% obese, 67% deceased donor, and 43% preoperative antithrombotic use). Forty (9.3%) patients required early postoperative transfusion (mean: 2.8 pRBCs/transfusion) and most did not require blood urgently. Only 20 (4.7%) patients required a transfusion intraoperatively or on the same day of surgery. Lower preoperative hemoglobin (per g/L unit: odds ratio [OR]: 0.943), female gender (OR: 2.752), and preoperative antithrombotic use (OR 2.369) were associated with a need for early postoperative transfusion. Conclusion: Transfusion in the early postoperative period following renal transplantation was less than 10%, suggesting that routine crossmatch may not be necessary for all patients. Preoperative hemoglobin, female gender, and preoperative antithrombotic use were associated with increased risk and may be useful to risk-stratify patients who require crossmatch.